首页 > 最新文献

Scandinavian Journal of Gastroenterology最新文献

英文 中文
Evaluation of the role of body mass index (BMI) in the association between dietary inflammatory index and non-alcoholic fatty liver diseases: a letter to editor. 评估体重指数(BMI)在膳食炎症指数与非酒精性脂肪肝之间关系中的作用:致编辑的一封信。
IF 1.6 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 Epub Date: 2024-02-28 DOI: 10.1080/00365521.2024.2323513
Matin Sepehrinia, Hossein Pourmontaseri
{"title":"Evaluation of the role of body mass index (BMI) in the association between dietary inflammatory index and non-alcoholic fatty liver diseases: a letter to editor.","authors":"Matin Sepehrinia, Hossein Pourmontaseri","doi":"10.1080/00365521.2024.2323513","DOIUrl":"10.1080/00365521.2024.2323513","url":null,"abstract":"","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"761"},"PeriodicalIF":1.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139983713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors and management of iatrogenic colorectal perforation in diagnostic colonoscopy: a single-center cohort study. 诊断性结肠镜检查中先天性结肠直肠穿孔的风险因素和处理方法:一项单中心队列研究。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 Epub Date: 2024-02-21 DOI: 10.1080/00365521.2024.2316766
Aryoung Kim, Heejung Kim, Eun Ran Kim, Ji Eun Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim

Background and aims: Diagnostic colonoscopy plays a central role in colorectal cancer screening programs. We analyzed the risk factors for perforation during diagnostic colonoscopy and discussed the treatment outcomes.

Methods: We performed a retrospective analysis of risk factors and treatment outcomes of perforation during 74,426 diagnostic colonoscopies between 2013 and 2018 in a tertiary hospital.

Results: A total of 19 perforations were identified after 74,426 diagnostic colonoscopies or sigmoidoscopies, resulting in a standardized incidence rate of 0.025% or 2.5 per 10,000 colonoscopies. The majority (15 out of 19, 79%) were found at the sigmoid colon and recto-sigmoid junction. Perforation occurred mostly in less than 1000 cases of colonoscopy (16 out of 19, 84%). In particular, the incidence of perforation was higher in more than 200 cases undergoing slightly advanced colonoscopy rather than beginners who had just learned colonoscopy. Old age (≥ 70 years), inpatient setting, low body mass index (BMI), and sedation status were significantly associated with increased risk of perforation. Nine (47%) of the patients underwent operative treatment and ten (53%) were managed non-operatively. Patients who underwent surgery were often diagnosed with delayed or concomitant abdominal pain. Perforations of rectum tended to be successfully treated with endoscopic clipping.

Conclusions: Additional precautions are required to prevent perforation in elderly patients, hospital settings, low BMI, sedated patients, or by a doctor with slight familiarity with endoscopies (but still insufficient experience). Endoscopic treatment should be actively considered if diagnosis is prompt, abdominal pain absent, and especially the rectal perforation is present.

背景和目的:诊断性结肠镜检查在结直肠癌筛查项目中发挥着核心作用。我们分析了诊断性结肠镜检查中穿孔的风险因素,并讨论了治疗结果:我们对一家三甲医院 2013 年至 2018 年期间的 74426 例诊断性肠镜检查中穿孔的风险因素和治疗结果进行了回顾性分析:在74426例诊断性结肠镜或乙状结肠镜检查后,共发现19例穿孔,标准化发病率为0.025%,即每10000例结肠镜检查中有2.5例穿孔。大多数(19 例中的 15 例,79%)穿孔发生在乙状结肠和直肠-乙状结肠交界处。穿孔大多发生在不足 1000 例的结肠镜检查中(19 例中有 16 例,占 84%)。特别是在 200 多例接受稍微高级结肠镜检查的病例中,穿孔的发生率要高于刚刚学习结肠镜检查的初学者。高龄(≥ 70 岁)、住院环境、低体重指数(BMI)和镇静状态与穿孔风险增加显著相关。九名患者(47%)接受了手术治疗,十名患者(53%)接受了非手术治疗。接受手术治疗的患者通常是因腹痛延迟或并发腹痛而确诊的。直肠穿孔往往通过内窥镜剪切术成功治疗:在老年患者、医院环境、低体重指数(BMI)、服用镇静剂的患者或对内窥镜略有了解(但经验仍然不足)的医生操作时,需要采取额外的预防措施以防止穿孔。如果诊断及时、无腹痛,尤其是出现直肠穿孔,应积极考虑内镜治疗。
{"title":"Risk factors and management of iatrogenic colorectal perforation in diagnostic colonoscopy: a single-center cohort study.","authors":"Aryoung Kim, Heejung Kim, Eun Ran Kim, Ji Eun Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim","doi":"10.1080/00365521.2024.2316766","DOIUrl":"10.1080/00365521.2024.2316766","url":null,"abstract":"<p><strong>Background and aims: </strong>Diagnostic colonoscopy plays a central role in colorectal cancer screening programs. We analyzed the risk factors for perforation during diagnostic colonoscopy and discussed the treatment outcomes.</p><p><strong>Methods: </strong>We performed a retrospective analysis of risk factors and treatment outcomes of perforation during 74,426 diagnostic colonoscopies between 2013 and 2018 in a tertiary hospital.</p><p><strong>Results: </strong>A total of 19 perforations were identified after 74,426 diagnostic colonoscopies or sigmoidoscopies, resulting in a standardized incidence rate of 0.025% or 2.5 per 10,000 colonoscopies. The majority (15 out of 19, 79%) were found at the sigmoid colon and recto-sigmoid junction. Perforation occurred mostly in less than 1000 cases of colonoscopy (16 out of 19, 84%). In particular, the incidence of perforation was higher in more than 200 cases undergoing slightly advanced colonoscopy rather than beginners who had just learned colonoscopy. Old age (≥ 70 years), inpatient setting, low body mass index (BMI), and sedation status were significantly associated with increased risk of perforation. Nine (47%) of the patients underwent operative treatment and ten (53%) were managed non-operatively. Patients who underwent surgery were often diagnosed with delayed or concomitant abdominal pain. Perforations of rectum tended to be successfully treated with endoscopic clipping.</p><p><strong>Conclusions: </strong>Additional precautions are required to prevent perforation in elderly patients, hospital settings, low BMI, sedated patients, or by a doctor with slight familiarity with endoscopies (but still insufficient experience). Endoscopic treatment should be actively considered if diagnosis is prompt, abdominal pain absent, and especially the rectal perforation is present.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"749-754"},"PeriodicalIF":1.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139913426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma. 甘草酸通过靶向肝细胞癌的mTOR信号转导诱导铁变态反应,从而减轻索拉非尼的耐药性
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 Epub Date: 2024-03-01 DOI: 10.1080/00365521.2024.2315317
Yiting Hu, Zhongfei Luo, Siyi Cai, Qinfen Xie, Shusen Zheng

Background: Hepatocellular carcinoma (HCC) is the most malignant cancer worldwide. Sorafenib (SRF) is a common therapeutic drug used for patients with advanced HCC. Nevertheless, drug resistance frequently occurs in patients treated with sorafenib. Glycyrrhizic acid (GRA) is a natural compound that is identified to exhibit anti-cancer effects. In this work, we aimed to investigate the effects of GRA on SRF-resistant HCC cells and the potential regulatory mechanisms.

Methods: We established SRF-resistant HCC cell lines and administrated GRA treatment. We performed CCK-8 and colony formation experiments to detect cell proliferation. The accumulation of lipid reactive oxygen species (ROS) and iron levels were measured to evaluate ferroptosis. The protein levels of ferroptosis suppressor glutathione peroxidase 4 (GPX4) and SLC7A11, and the activation of AKT and mTOR were measured with western blotting assay.

Results: GRA treatment notably suppressed the viability and proliferation of SRF-resistant HCC cells. SRF-resistant HCC cells exhibited repressed ferroptosis level activated AKT/mTOR cascade, and GRA treatment reversed these effects. Inhibition of ferroptosis and activation of mTOR reversed the anti-proliferation effects of GRA on SRF-resistant HCC cells.

Conclusion: Treatment with GRA could effectively reverse the SRF resistance of HCC cells via inducing ferroptosis and inactivating the AKT/mTOR cascade.

背景:肝细胞癌(HCC)是全球发病率最高的恶性肿瘤。索拉非尼(SRF)是晚期肝细胞癌患者常用的治疗药物。然而,接受索拉非尼治疗的患者经常出现耐药性。甘草酸(GRA)是一种被确认具有抗癌作用的天然化合物。在这项工作中,我们旨在研究 GRA 对 SRF 耐药 HCC 细胞的影响及其潜在的调控机制:方法:我们建立了 SRF 抗性 HCC 细胞系,并给予 GRA 处理。我们进行了 CCK-8 和集落形成实验来检测细胞增殖。测量脂质活性氧(ROS)的积累和铁的水平以评估铁变态反应。用 Western 印迹法测定了铁变态反应抑制因子谷胱甘肽过氧化物酶 4 (GPX4) 和 SLC7A11 的蛋白水平,以及 AKT 和 mTOR 的活化情况:结果:GRA处理显著抑制了SRF耐药HCC细胞的活力和增殖。SRF耐药的HCC细胞表现出抑铁水平的AKT/mTOR级联激活,而GRA处理可逆转这些效应。抑制高铁血症和激活mTOR逆转了GRA对SRF耐药HCC细胞的抗增殖作用:结论:GRA能通过诱导铁变态反应和激活AKT/mTOR级联有效逆转HCC细胞对SRF的耐药性。
{"title":"Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.","authors":"Yiting Hu, Zhongfei Luo, Siyi Cai, Qinfen Xie, Shusen Zheng","doi":"10.1080/00365521.2024.2315317","DOIUrl":"10.1080/00365521.2024.2315317","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the most malignant cancer worldwide. Sorafenib (SRF) is a common therapeutic drug used for patients with advanced HCC. Nevertheless, drug resistance frequently occurs in patients treated with sorafenib. Glycyrrhizic acid (GRA) is a natural compound that is identified to exhibit anti-cancer effects. In this work, we aimed to investigate the effects of GRA on SRF-resistant HCC cells and the potential regulatory mechanisms.</p><p><strong>Methods: </strong>We established SRF-resistant HCC cell lines and administrated GRA treatment. We performed CCK-8 and colony formation experiments to detect cell proliferation. The accumulation of lipid reactive oxygen species (ROS) and iron levels were measured to evaluate ferroptosis. The protein levels of ferroptosis suppressor glutathione peroxidase 4 (GPX4) and SLC7A11, and the activation of AKT and mTOR were measured with western blotting assay.</p><p><strong>Results: </strong>GRA treatment notably suppressed the viability and proliferation of SRF-resistant HCC cells. SRF-resistant HCC cells exhibited repressed ferroptosis level activated AKT/mTOR cascade, and GRA treatment reversed these effects. Inhibition of ferroptosis and activation of mTOR reversed the anti-proliferation effects of GRA on SRF-resistant HCC cells.</p><p><strong>Conclusion: </strong>Treatment with GRA could effectively reverse the SRF resistance of HCC cells <i>via</i> inducing ferroptosis and inactivating the AKT/mTOR cascade.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"730-736"},"PeriodicalIF":1.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congenital sucrase-isomaltase deficiency in Türkiye; a single center experience. 土耳其的先天性蔗糖异麦芽糖酶缺乏症;单个中心的经验。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 Epub Date: 2024-03-08 DOI: 10.1080/00365521.2024.2324961
Doğan Barut, Ezgi Kıran Taşcı, Bora Kunay, Burcu Güven, Betül Aksoy, Yeliz Çağan Appak, Miray Karakoyun, Funda Çetin, Ayşe Selimoğlu, Huseyin Onay, Sema Aydoğdu

Background: Congenital sucrase-isomaltase deficiency (CSID) is a rare inherited carbohydrate malabsorption disorder caused by sucrase-isomaltase (SI) gene variants. In CSID, an autosomal recessively inherited disease, symptoms can also be seen in individuals with heterozygous mutations.

Methods: The variant spectrum was evaluated retrospectively in individuals who presented with chronic diarrhea between 2014 and 2022 and had undergone genetic testing of the SI gene considering CSID due to diet-related complaints.

Results: Ten patients with chronic diarrhea were genetically evaluated with SI gene sequencing. In patients diagnosed with CSID and whose symptoms improved with enzyme replacement therapy, the genetic mutation zygosity was found to be heterozygous at a rate of 90%. In 10% of the patients, the mutation was homozygous. Limiting consuming sucrose and isomaltose foods reduced the patients' complaints, but the symptoms did not disappear completely. With the initiation of sacrosidase enzyme replacement therapy, the patient's complaints completely disappeared.

Conclusion: In CSID, defined as an autosomal recessive disease, clinical symptoms can also be seen in heterozygous cases previously described as carriers, and these patients also benefit from sacrosidase enzyme replacement therapy. In light of these findings, the autosomal recessive definition of CSID does not fully characterize the disease.What is Known:CSID is a rare inherited carbohydrate malabsorption disorder caused by sucrase-isomaltase gene variants.In congenital sucrase-isomaltase deficiency, an autosomal recessively inherited disorder, symptoms can also be seen in individuals with heterozygous mutations.What is new:Severe disease symptoms can also be seen in heterozygous cases, which were thought to be carriers because the disease was previously described as autosomal recessive.Sacrosidase enzyme replacement therapy also eliminates the disease symptoms in patients with heterozygous CSID mutations.This is the second study on sucrase-isomaltase enzyme deficiency pediatric groups in Türkiye and Europe.

背景:先天性蔗糖异麦芽糖酶缺乏症(CSID)是一种罕见的遗传性碳水化合物吸收不良疾病,由蔗糖异麦芽糖酶(SI)基因变异引起。CSID 是一种常染色体隐性遗传疾病,杂合突变个体也可出现症状:方法:对2014年至2022年期间出现慢性腹泻,并因饮食相关主诉而接受SI基因检测以考虑CSID的患者进行变异谱回顾性评估:对10名慢性腹泻患者进行了SI基因测序遗传学评估。在被确诊为 CSID 并接受酶替代疗法后症状有所改善的患者中,发现基因突变杂合率为 90%。10%的患者基因突变为同型。限制食用蔗糖和异麦芽糖食物减轻了患者的不适,但症状并未完全消失。在开始使用蔗糖酶替代治疗后,患者的症状完全消失:结论:CSID 被定义为常染色体隐性遗传病,在以前被描述为携带者的杂合子病例中也可出现临床症状,这些患者也可从蔗糖酶替代疗法中获益。已知病例:CSID是一种罕见的遗传性碳水化合物吸收不良症,由蔗糖酶-异麦芽糖酶基因变异引起。先天性蔗糖酶-异麦芽糖酶缺乏症是一种常染色体隐性遗传疾病,杂合子突变个体也可出现症状。新发现:在杂合子病例中也可出现严重的疾病症状,由于该病以前被描述为常染色体隐性遗传病,因此被认为是携带者。蔗糖酶酶替代疗法也可消除杂合子CSID突变患者的疾病症状。
{"title":"Congenital sucrase-isomaltase deficiency in Türkiye; a single center experience.","authors":"Doğan Barut, Ezgi Kıran Taşcı, Bora Kunay, Burcu Güven, Betül Aksoy, Yeliz Çağan Appak, Miray Karakoyun, Funda Çetin, Ayşe Selimoğlu, Huseyin Onay, Sema Aydoğdu","doi":"10.1080/00365521.2024.2324961","DOIUrl":"10.1080/00365521.2024.2324961","url":null,"abstract":"<p><strong>Background: </strong>Congenital sucrase-isomaltase deficiency (CSID) is a rare inherited carbohydrate malabsorption disorder caused by <i>sucrase-isomaltase</i> (<i>SI</i>) gene variants. In CSID, an autosomal recessively inherited disease, symptoms can also be seen in individuals with heterozygous mutations.</p><p><strong>Methods: </strong>The variant spectrum was evaluated retrospectively in individuals who presented with chronic diarrhea between 2014 and 2022 and had undergone genetic testing of the <i>SI</i> gene considering CSID due to diet-related complaints.</p><p><strong>Results: </strong>Ten patients with chronic diarrhea were genetically evaluated with <i>SI</i> gene sequencing. In patients diagnosed with CSID and whose symptoms improved with enzyme replacement therapy, the genetic mutation zygosity was found to be heterozygous at a rate of 90%. In 10% of the patients, the mutation was homozygous. Limiting consuming sucrose and isomaltose foods reduced the patients' complaints, but the symptoms did not disappear completely. With the initiation of sacrosidase enzyme replacement therapy, the patient's complaints completely disappeared.</p><p><strong>Conclusion: </strong>In CSID, defined as an autosomal recessive disease, clinical symptoms can also be seen in heterozygous cases previously described as carriers, and these patients also benefit from sacrosidase enzyme replacement therapy. In light of these findings, the autosomal recessive definition of CSID does not fully characterize the disease.What is Known:CSID is a rare inherited carbohydrate malabsorption disorder caused by <i>sucrase-isomaltase</i> gene variants.In congenital sucrase-isomaltase deficiency, an autosomal recessively inherited disorder, symptoms can also be seen in individuals with heterozygous mutations.What is new:Severe disease symptoms can also be seen in heterozygous cases, which were thought to be carriers because the disease was previously described as autosomal recessive.Sacrosidase enzyme replacement therapy also eliminates the disease symptoms in patients with heterozygous CSID mutations.<b>This is the second study on sucrase-isomaltase enzyme deficiency pediatric groups in Türkiye and Europe.</b></p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"647-651"},"PeriodicalIF":1.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma. 关于无法手术的晚期或局部晚期食道鳞状细胞癌患者接受免疫疗法前外周血炎症指标预测价值的研究。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 Epub Date: 2024-02-16 DOI: 10.1080/00365521.2024.2319319
Maodong Fu, Zhiyong Li, Jun Ma, Feng Shen, Xiuping Zhang

Objective: To explore the effects of pretreatment peripheral blood panimmune-inflammation value (PIV), systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) on the efficacy and prognostic value of immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma (ESCC).

Methods: Clinical data of 107 inoperable advanced or locally advanced ESCC patients were retrospectively analysed between May 2019 and August 2023, the receiver operating characteristic curves (ROCs) of PIV, SII, NLR, and PLR in patients prior to immunotherapy were plotted, and their optimal cutoff values were determined. The risk factors were determined by univariate and multivariate analyses in groups based on the optimal cut-off values.

Results: Peripheral blood PIV, SII and PLR before immunotherapy had predictive value for the optimal efficacy of immunotherapy in patients with inoperable advanced or locally advanced ESCC; patients with PIV ≥415.885, SII ≥834.295 and NLR ≥3.740 had a low objective response rate (ORR), disease control rate (DCR), a short progression-free survival (PFS) and overall survival (OS) after immunotherapy (p < 0.05). Patient tumour stage, distant lymph node metastasis, lung metastasis, liver metastasis, PIV, SII, and NLR were risk factors affecting PFS and OS (p < 0.05). Tumour stage and SII were independent risk factors affecting PFS and OS (p < 0.05).

Conclusion: In patients with inoperable advanced or locally advanced ESCC, peripheral blood PIV, SII, and NLR have predictive value for immunotherapy outcome, SII is an independent risk factor affecting the survival prognosis, and SII ≥834.295 suggests a poor prognosis from immunotherapy.

目的探讨不能手术的晚期或局部晚期食管鳞癌(ESCC)患者治疗前外周血泛免疫炎症值(PIV)、全身免疫炎症指数(SII)、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)对免疫治疗疗效及预后的影响:回顾性分析2019年5月至2023年8月期间107例无法手术的晚期或局部晚期ESCC患者的临床数据,绘制免疫治疗前患者PIV、SII、NLR和PLR的接收者操作特征曲线(ROC),并确定其最佳临界值。根据最佳临界值进行分组,通过单变量和多变量分析确定风险因素:结果:免疫治疗前外周血PIV、SII和PLR对无法手术的晚期或局部晚期ESCC患者免疫治疗的最佳疗效具有预测价值;PIV≥415.885、SII≥834.295和NLR≥3.740的患者免疫治疗后客观反应率(ORR)、疾病控制率(DCR)低,无进展生存期(PFS)和总生存期(OS)短(p p p 结论:免疫治疗前外周血PIV、SII和PLR对无法手术的晚期或局部晚期ESCC患者免疫治疗的最佳疗效具有预测价值:在无法手术的晚期或局部晚期ESCC患者中,外周血PIV、SII和NLR对免疫治疗结果有预测价值,SII是影响生存预后的独立危险因素,SII≥834.295提示免疫治疗预后不良。
{"title":"Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma.","authors":"Maodong Fu, Zhiyong Li, Jun Ma, Feng Shen, Xiuping Zhang","doi":"10.1080/00365521.2024.2319319","DOIUrl":"10.1080/00365521.2024.2319319","url":null,"abstract":"<p><strong>Objective: </strong>To explore the effects of pretreatment peripheral blood panimmune-inflammation value (PIV), systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) on the efficacy and prognostic value of immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma (ESCC).</p><p><strong>Methods: </strong>Clinical data of 107 inoperable advanced or locally advanced ESCC patients were retrospectively analysed between May 2019 and August 2023, the receiver operating characteristic curves (ROCs) of PIV, SII, NLR, and PLR in patients prior to immunotherapy were plotted, and their optimal cutoff values were determined. The risk factors were determined by univariate and multivariate analyses in groups based on the optimal cut-off values.</p><p><strong>Results: </strong>Peripheral blood PIV, SII and PLR before immunotherapy had predictive value for the optimal efficacy of immunotherapy in patients with inoperable advanced or locally advanced ESCC; patients with PIV ≥415.885, SII ≥834.295 and NLR ≥3.740 had a low objective response rate (ORR), disease control rate (DCR), a short progression-free survival (PFS) and overall survival (OS) after immunotherapy (<i>p</i> < 0.05). Patient tumour stage, distant lymph node metastasis, lung metastasis, liver metastasis, PIV, SII, and NLR were risk factors affecting PFS and OS (<i>p</i> < 0.05). Tumour stage and SII were independent risk factors affecting PFS and OS (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>In patients with inoperable advanced or locally advanced ESCC, peripheral blood PIV, SII, and NLR have predictive value for immunotherapy outcome, SII is an independent risk factor affecting the survival prognosis, and SII ≥834.295 suggests a poor prognosis from immunotherapy.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"722-729"},"PeriodicalIF":1.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139741930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liquid biopsy of oesophageal squamous cell carcinoma: implications in diagnosis, prognosis, and treatment monitoring. 食管鳞状细胞癌的液体活检:对诊断、预后和治疗监测的影响。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 Epub Date: 2024-03-11 DOI: 10.1080/00365521.2024.2310167
Mei-Juan Hao, Zhi-Yuan Cheng, Ye Gao, Lei Xin, Chu-Ting Yu, Ting-Lu Wang, Zhao-Shen Li, Luo-Wei Wang

Oesophageal squamous cell carcinoma (ESCC) is a common malignant tumour of the gastrointestinal tract. Early detection and access to appropriate treatment are crucial for the long-term survival of patients. However, limited diagnostic and monitoring methods are available for identifying early stage ESCC. Endoscopic screening and surgical resection are commonly used to diagnose and treat early ESCC. However, these methods have disadvantages, such as high recurrence, lethality, and mortality rates. Therefore, methods to improve early diagnosis of ESCC and reduce its mortality rate are urgently required. In 1961, Gary et al. proposed a novel liquid biopsy approach for clinical diagnosis. This involved examining exosomes, circulating tumour cells, circulating free DNA, and circulating free RNA in body fluids. The ability of liquid biopsy to obtain samples repeatedly, wide detection range, and fast detection speed make it a feasible option for non-invasive tumour detection. In clinical practice, liquid biopsy technology has gained popularity for early screening, diagnosis, treatment efficacy monitoring, and prognosis assessment. Thus, this is a highly promising examination method. However, there have been no comprehensive reviews on the four factors of liquid biopsy in the context of ESCC. This review aimed to analyse the progress of liquid biopsy research for ESCC, including its classification, components, and potential future applications.

食管鳞状细胞癌(ESCC)是胃肠道常见的恶性肿瘤。早期发现并获得适当的治疗对患者的长期生存至关重要。然而,目前用于识别早期 ESCC 的诊断和监测方法有限。内窥镜筛查和手术切除是诊断和治疗早期 ESCC 的常用方法。然而,这些方法都有缺点,如复发率高、致死率高和死亡率高。因此,提高 ESCC 早期诊断率和降低其死亡率的方法迫在眉睫。1961 年,Gary 等人提出了一种用于临床诊断的新型液体活检方法。这包括检查体液中的外泌体、循环肿瘤细胞、循环游离 DNA 和循环游离 RNA。液体活检可反复获取样本,检测范围广,检测速度快,是一种可行的无创肿瘤检测方法。在临床实践中,液体活检技术已在早期筛查、诊断、疗效监测和预后评估方面得到普及。因此,这是一种极具前景的检查方法。然而,目前还没有针对 ESCC 的液体活检四要素的全面综述。本综述旨在分析针对 ESCC 的液体活检研究进展,包括其分类、组成部分和未来的潜在应用。
{"title":"Liquid biopsy of oesophageal squamous cell carcinoma: implications in diagnosis, prognosis, and treatment monitoring.","authors":"Mei-Juan Hao, Zhi-Yuan Cheng, Ye Gao, Lei Xin, Chu-Ting Yu, Ting-Lu Wang, Zhao-Shen Li, Luo-Wei Wang","doi":"10.1080/00365521.2024.2310167","DOIUrl":"10.1080/00365521.2024.2310167","url":null,"abstract":"<p><p>Oesophageal squamous cell carcinoma (ESCC) is a common malignant tumour of the gastrointestinal tract. Early detection and access to appropriate treatment are crucial for the long-term survival of patients. However, limited diagnostic and monitoring methods are available for identifying early stage ESCC. Endoscopic screening and surgical resection are commonly used to diagnose and treat early ESCC. However, these methods have disadvantages, such as high recurrence, lethality, and mortality rates. Therefore, methods to improve early diagnosis of ESCC and reduce its mortality rate are urgently required. In 1961, Gary et al. proposed a novel liquid biopsy approach for clinical diagnosis. This involved examining exosomes, circulating tumour cells, circulating free DNA, and circulating free RNA in body fluids. The ability of liquid biopsy to obtain samples repeatedly, wide detection range, and fast detection speed make it a feasible option for non-invasive tumour detection. In clinical practice, liquid biopsy technology has gained popularity for early screening, diagnosis, treatment efficacy monitoring, and prognosis assessment. Thus, this is a highly promising examination method. However, there have been no comprehensive reviews on the four factors of liquid biopsy in the context of ESCC. This review aimed to analyse the progress of liquid biopsy research for ESCC, including its classification, components, and potential future applications.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"698-709"},"PeriodicalIF":1.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparison of Swedish IBS patients and general practitioners regarding viewpoints on IBS: a Q-methodology study. 瑞典肠易激综合征患者与全科医生对肠易激综合征观点的比较:一项 Q 方法研究。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-01 Epub Date: 2024-04-01 DOI: 10.1080/00365521.2024.2328590
Jussi Rauma, Stefan Jansson, Yang Cao, Michiel A van Nieuwenhoven

Objectives: Irritable bowel syndrome (IBS) is a common functional gastrointestinal condition. A respectful patient-doctor relationship with good communication is crucial for optimal treatment. Q-methodology is a combination of qualitative and quantitative methods used to study subjectivity. The aim of this study was to compare viewpoints on IBS between patients with IBS and general practitioners (GPs).

Methods: We conducted a Q-methodology study by including 30 patients and 30 GPs. All participants were asked to complete Q- sorting of 66 statements on IBS using an online software program. Data were processed using factor analysis. In addition, 3 patients and 3 GPs were interviewed.

Results: Three factors were extracted from both groups: Patient Factor 1 'Question the diagnosis of IBS', Patient Factor 2 'Lifestyle changes for a physical disorder', Patient Factor 3 'Importance of a diagnosis', GP Factor 1 'Unknown causes of great suffering', GP Factor 2 'Lifestyle changes are important, stress makes IBS worse', GP Factor 3 'Recognized the way IBS affects patients'. There was a strong and statistically significant correlation between patient Factor 1 and GP Factor 1, with a Pearson's r of 0.81 (p < 0.001). Correlations between other factors varied.

Conclusions: There was consensus between patients and GPs that IBS is a physical and not a psychiatric disorder of unknown etiology. They also seemed to agree that IBS has a great negative impact on patients' lives and that lifestyle changes are beneficial. There were conflicting opinions regarding gender, cultural factors and the use of antidepressants.

目的:肠易激综合征(IBS)是一种常见的功能性胃肠道疾病。尊重患者、保持良好沟通的医患关系对于优化治疗至关重要。Q 方法是一种定性和定量相结合的方法,用于研究主观性。本研究旨在比较肠易激综合征患者和全科医生(GPs)对肠易激综合征的看法:我们进行了一项 Q 方法研究,包括 30 名患者和 30 名全科医生。所有参与者都被要求使用一个在线软件程序对有关肠易激综合征的 66 条陈述进行 Q 排序。数据采用因子分析法进行处理。此外,还对 3 名患者和 3 名全科医生进行了访谈:结果:从两组数据中提取了三个因子:患者因子 1 "质疑肠易激综合征的诊断"、患者因子 2 "改变生活方式治疗身体疾病"、患者因子 3 "诊断的重要性"、全科医生因子 1 "巨大痛苦的未知原因"、全科医生因子 2 "改变生活方式很重要,压力会使肠易激综合征恶化"、全科医生因子 3 "认识到肠易激综合征对患者的影响"。患者因子 1 与全科医生因子 1 之间存在很强的统计学意义上的相关性,Pearson's r 为 0.81(p 结论:患者因子 1 与全科医生因子 1 之间存在很强的统计学意义上的相关性,Pearson's r 为 0.81:患者和全科医生一致认为肠易激综合征是一种病因不明的躯体疾病,而非精神疾病。他们似乎还一致认为肠易激综合征对患者的生活有很大的负面影响,而改变生活方式是有益的。在性别、文化因素和抗抑郁药物的使用方面存在意见分歧。
{"title":"A comparison of Swedish IBS patients and general practitioners regarding viewpoints on IBS: a Q-methodology study.","authors":"Jussi Rauma, Stefan Jansson, Yang Cao, Michiel A van Nieuwenhoven","doi":"10.1080/00365521.2024.2328590","DOIUrl":"10.1080/00365521.2024.2328590","url":null,"abstract":"<p><strong>Objectives: </strong>Irritable bowel syndrome (IBS) is a common functional gastrointestinal condition. A respectful patient-doctor relationship with good communication is crucial for optimal treatment. Q-methodology is a combination of qualitative and quantitative methods used to study subjectivity. The aim of this study was to compare viewpoints on IBS between patients with IBS and general practitioners (GPs).</p><p><strong>Methods: </strong>We conducted a Q-methodology study by including 30 patients and 30 GPs. All participants were asked to complete Q- sorting of 66 statements on IBS using an online software program. Data were processed using factor analysis. In addition, 3 patients and 3 GPs were interviewed.</p><p><strong>Results: </strong>Three factors were extracted from both groups: Patient Factor 1 'Question the diagnosis of IBS', Patient Factor 2 'Lifestyle changes for a physical disorder', Patient Factor 3 'Importance of a diagnosis', GP Factor 1 'Unknown causes of great suffering', GP Factor 2 'Lifestyle changes are important, stress makes IBS worse', GP Factor 3 'Recognized the way IBS affects patients'. There was a strong and statistically significant correlation between patient Factor 1 and GP Factor 1, with a Pearson's r of 0.81 (<i>p</i> < 0.001). Correlations between other factors varied.</p><p><strong>Conclusions: </strong>There was consensus between patients and GPs that IBS is a physical and not a psychiatric disorder of unknown etiology. They also seemed to agree that IBS has a great negative impact on patients' lives and that lifestyle changes are beneficial. There were conflicting opinions regarding gender, cultural factors and the use of antidepressants.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"632-638"},"PeriodicalIF":1.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140336763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strict diagnostic criteria can lead to underestimation of risk of acute diverticulitis. 严格的诊断标准可能导致低估急性憩室炎的风险。
IF 1.6 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-01 Epub Date: 2024-02-08 DOI: 10.1080/00365521.2024.2314144
Osman Cagin Buldukoglu, Serkan Ocal, Ayhan Hilmi Cekin
{"title":"Strict diagnostic criteria can lead to underestimation of risk of acute diverticulitis.","authors":"Osman Cagin Buldukoglu, Serkan Ocal, Ayhan Hilmi Cekin","doi":"10.1080/00365521.2024.2314144","DOIUrl":"10.1080/00365521.2024.2314144","url":null,"abstract":"","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"631"},"PeriodicalIF":1.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139703307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of enteral nutrition via percutaneous transhepatic cholangiography drainage catheterization in late-stage malignant obstructive jaundice. 通过经皮经肝胆管造影引流导管进行肠内营养对晚期恶性阻塞性黄疸的实用性。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-01 Epub Date: 2024-01-22 DOI: 10.1080/00365521.2024.2305274
Jian-Hua Cao, Zhan-Hu Mu, Hai-Ming Li, Gao-Xiang Li, Jie Chen, Jian-Jun Yao, Xue-Wen Yang, Sheng Wang

Objective: The purpose of this study was to explore the clinical benefits of establishing an enteral nutrition (EN) pathway via percutaneous transhepatic cholangiography drainage (PTCD) catheterization in patients with late-stage malignant obstructive jaundice (MOJ).Methods: We selected 30 patients diagnosed as having late-stage MOJ with malnutrition. A dual-lumen biliary-enteral nutrition tube was placed via PTCD along with a biliary stent implantation. Postoperative EN was provided, and we observed the time taken for tube placement, its success rate, complications, and therapeutic efficacy.Results: Tube placement was successful in all 30 patients with an average procedural time of 5.7 ± 1.4 min with no tube placement complications. Compared to preoperative measures, there was a significant improvement in postoperative jaundice reduction and nutritional indicators one month after the procedure (p < 0.05). Post-placement complications included tube perileakage in 5 cases, entero-biliary reflux in 4 cases, tube blockage in 6 cases, tube displacement in 4 cases, accidental tube removal in 3 cases, and tube replacement due to degradation in 8 cases, with tube retention time ranging from 42 to 314 days, averaging 124.7 ± 37.5 days. All patients achieved the parameters for effective home-based enteral nutrition with a noticeable improvement in their quality of life.Conclusion: In this study, we found that the technique of establishing an EN pathway via PTCD catheterization was minimally invasive, safe, and effective; the tube was easy to maintain; and patient compliance was high. It is, thus, suitable for long-term tube retention in patients with late-stage MOJ.

研究目的本研究旨在探讨通过经皮经肝胆管造影引流术(PTCD)导管建立肠内营养(EN)途径对晚期恶性阻塞性黄疸(MOJ)患者的临床益处:我们选择了30名被诊断为晚期恶性梗阻性黄疸并伴有营养不良的患者。方法:我们选择了 30 名被诊断为晚期 MOJ 且伴有营养不良的患者,通过 PTCD 放置了双腔胆肠营养管,同时植入了胆道支架。我们提供了术后 EN,并观察了置管所需时间、成功率、并发症和疗效:结果:30 例患者均成功置管,平均手术时间为(5.7±1.4)分钟,无置管并发症。与术前相比,术后黄疸消退情况和术后一个月的营养指标均有明显改善(P 结论:在这项研究中,我们发现通过 PTCD 导管置管建立 EN 通路的技术是微创、安全和有效的;置管易于维护;患者依从性高。因此,该技术适用于 MOJ 晚期患者的长期置管。
{"title":"Utility of enteral nutrition via percutaneous transhepatic cholangiography drainage catheterization in late-stage malignant obstructive jaundice.","authors":"Jian-Hua Cao, Zhan-Hu Mu, Hai-Ming Li, Gao-Xiang Li, Jie Chen, Jian-Jun Yao, Xue-Wen Yang, Sheng Wang","doi":"10.1080/00365521.2024.2305274","DOIUrl":"10.1080/00365521.2024.2305274","url":null,"abstract":"<p><p><b>Objective:</b> The purpose of this study was to explore the clinical benefits of establishing an enteral nutrition (EN) pathway <i>via</i> percutaneous transhepatic cholangiography drainage (PTCD) catheterization in patients with late-stage malignant obstructive jaundice (MOJ).<b>Methods:</b> We selected 30 patients diagnosed as having late-stage MOJ with malnutrition. A dual-lumen biliary-enteral nutrition tube was placed <i>via</i> PTCD along with a biliary stent implantation. Postoperative EN was provided, and we observed the time taken for tube placement, its success rate, complications, and therapeutic efficacy.<b>Results:</b> Tube placement was successful in all 30 patients with an average procedural time of 5.7 ± 1.4 min with no tube placement complications. Compared to preoperative measures, there was a significant improvement in postoperative jaundice reduction and nutritional indicators one month after the procedure (<i>p</i> < 0.05). Post-placement complications included tube perileakage in 5 cases, entero-biliary reflux in 4 cases, tube blockage in 6 cases, tube displacement in 4 cases, accidental tube removal in 3 cases, and tube replacement due to degradation in 8 cases, with tube retention time ranging from 42 to 314 days, averaging 124.7 ± 37.5 days. All patients achieved the parameters for effective home-based enteral nutrition with a noticeable improvement in their quality of life.<b>Conclusion:</b> In this study, we found that the technique of establishing an EN pathway <i>via</i> PTCD catheterization was minimally invasive, safe, and effective; the tube was easy to maintain; and patient compliance was high. It is, thus, suitable for long-term tube retention in patients with late-stage MOJ.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"570-576"},"PeriodicalIF":1.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139521863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum ferritin level is associated with liver fibrosis and incident liver-related outcomes independent of HFE genotype in the general population. 在普通人群中,血清铁蛋白水平与肝纤维化和与肝脏相关的事件结果有关,与 HFE 基因型无关。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-01 Epub Date: 2024-02-08 DOI: 10.1080/00365521.2024.2314707
Ville T Männistö, Konsta Hakkarainen, Antti Jula, Annamari Lundqvist, Terhi Vihervaara, Iris Erlund, Fredrik Åberg

Background & aims: Hyperferritinemia reflects iron accumulation in the body and has been associated with metabolic disturbances and alcohol use, and is also a common finding in individuals diagnosed with liver disease. The major genetic regulator of iron metabolism is the HFE gene.

Methods: The aim of this this study was to investigate the association between serum ferritin and liver fibrosis using the enhanced liver fibrosis (ELF) test, and the association between ferritin and liver-related outcomes in a Finnish population-based cohort of 6194 individuals (45% male, mean [± standard deviation] age, 52.9 ± 14.9 years; body mass index 26.9 ± 4.7 kg/m2). The effects of HFE variants on these associations were also evaluated.

Results: Serum ferritin levels were significantly associated with liver fibrosis, as estimated by enhanced liver fibrosis (ELF) test in weighted linear regression analysis. Serum ferritin was significantly associated with both all liver-related outcomes (n = 92) and severe liver-related outcomes (n = 54) in weighted Cox regression analysis (hazard ratio [HR] per 1 SD, 1.11 [95% confidence interval (CI) 1.02-1.21]; p = 0.012 and HR 1.11 [95% CI 1.02-1.21]; p = 0.013, respectively). However, there was association neither between HFE risk variants and ELF test nor between HFE risk variants and liver-related outcomes.

Conclusion: Serum ferritin levels were associated with liver fibrosis and incident liver disease, independent of HFE genotype in the general population. Furthermore, data demonstrated that metabolic disturbances and alcohol use were major risk factors for hyperferritinemia.

背景与目的:高铁蛋白血症反映了体内铁的积累,与代谢紊乱和酗酒有关,也是肝病患者的常见症状。铁代谢的主要遗传调节因子是 HFE 基因:本研究的目的是通过增强肝纤维化(ELF)测试,调查血清铁蛋白与肝纤维化之间的关系,以及铁蛋白与肝脏相关结果之间的关系,研究对象为芬兰人口队列中的 6194 人(45% 为男性,平均 [± 标准差] 年龄为 52.9 ± 14.9 岁;体重指数为 26.9 ± 4.7 kg/m2)。此外,还评估了 HFE 变体对这些关联的影响:结果:血清铁蛋白水平与肝纤维化显著相关,肝纤维化增强(ELF)测试在加权线性回归分析中估算出了这一结果。在加权 Cox 回归分析中,血清铁蛋白与所有肝脏相关结果(n = 92)和严重肝脏相关结果(n = 54)显著相关(每 1 SD 的危险比 [HR] 分别为 1.11 [95% 置信区间 (CI) 1.02-1.21];p = 0.012 和 HR 1.11 [95% CI 1.02-1.21];p = 0.013)。然而,HFE风险变异与ELF测试之间以及HFE风险变异与肝脏相关结果之间均无关联:结论:在普通人群中,血清铁蛋白水平与肝纤维化和肝病的发生有关,与 HFE 基因型无关。此外,数据显示,代谢紊乱和饮酒是导致高铁蛋白血症的主要风险因素。
{"title":"Serum ferritin level is associated with liver fibrosis and incident liver-related outcomes independent of <i>HFE</i> genotype in the general population.","authors":"Ville T Männistö, Konsta Hakkarainen, Antti Jula, Annamari Lundqvist, Terhi Vihervaara, Iris Erlund, Fredrik Åberg","doi":"10.1080/00365521.2024.2314707","DOIUrl":"10.1080/00365521.2024.2314707","url":null,"abstract":"<p><strong>Background & aims: </strong>Hyperferritinemia reflects iron accumulation in the body and has been associated with metabolic disturbances and alcohol use, and is also a common finding in individuals diagnosed with liver disease. The major genetic regulator of iron metabolism is the <i>HFE</i> gene.</p><p><strong>Methods: </strong>The aim of this this study was to investigate the association between serum ferritin and liver fibrosis using the enhanced liver fibrosis (ELF) test, and the association between ferritin and liver-related outcomes in a Finnish population-based cohort of 6194 individuals (45% male, mean [± standard deviation] age, 52.9 ± 14.9 years; body mass index 26.9 ± 4.7 kg/m<sup>2</sup>). The effects of <i>HFE</i> variants on these associations were also evaluated.</p><p><strong>Results: </strong>Serum ferritin levels were significantly associated with liver fibrosis, as estimated by enhanced liver fibrosis (ELF) test in weighted linear regression analysis. Serum ferritin was significantly associated with both all liver-related outcomes (<i>n</i> = 92) and severe liver-related outcomes (<i>n</i> = 54) in weighted Cox regression analysis (hazard ratio [HR] per 1 SD, 1.11 [95% confidence interval (CI) 1.02-1.21]; <i>p</i> = 0.012 and HR 1.11 [95% CI 1.02-1.21]; <i>p</i> = 0.013, respectively). However, there was association neither between <i>HFE</i> risk variants and ELF test nor between <i>HFE</i> risk variants and liver-related outcomes.</p><p><strong>Conclusion: </strong>Serum ferritin levels were associated with liver fibrosis and incident liver disease, independent of <i>HFE</i> genotype in the general population. Furthermore, data demonstrated that metabolic disturbances and alcohol use were major risk factors for hyperferritinemia.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"592-599"},"PeriodicalIF":1.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139703306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Scandinavian Journal of Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1